FDA Extends Comment Period For Glucose Monitor Guidelines
This article was originally published in The Gray Sheet
The agency is giving product developers and others an additional month to comment on draft guidelines, issued in January, that distinguish pre-market requirements for glucose meters employed in professional health care settings from those intended for self-monitoring by patients.
You may also be interested in...
The agency for the first time issued distinct guidance documents for blood glucose meters used in professional settings and those issued over-the-counter for self-monitoring tests by lay-persons. FDA is collecting comments on draft versions of the guidelines.
Oncology Center of Excellence is reviewing a research report on fluorouracil, and will next look to update cisplatin's label, but eventually must convince the reference product sponsor to submit the changes.
US FDA’s ‘Project Renewal’ requires lots of work and flexibility, Oncology Center of Excellence acknowledges. Side-benefit may be getting outside physicians to appreciate the value of drug labeling.